• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无菌基础:静脉药物混合制剂的制备考量,第5部分:pH值考量

Sterile Basics: Intravenous Admixture Preparation Considerations, Part 5: pH Considerations.

作者信息

Allen Loyd V

机构信息

International Journal of Pharmaceutical Compounding.

出版信息

Int J Pharm Compd. 2020 Jul-Aug;24(4):305-309.

PMID:32649304
Abstract

The effect of pH on solubility and stability is a critical factor in the formulation of parenteral dosage forms and becomes more complicated in intravenous admixtures since the additives and the vehicle may have different pH values. This is especially important as a significant number of parenteral medications require some compounding involving dissolution of lyophilized powders, dilution of drug doses for infusion, mixing of dextrose, amino acids, vitamins, and electrolytes for parenteral nutrition, etc. A change in the acid-base environment of a drug involves both the solubility and stability characteristics and can be critically related to pH as follows:  (1) as a solution goes away from the pH of maximum solubility, the drug can precipitate out of solution, and  (2) as the solution goes away from the pH of maximum stability, the drug  can degrade more rapidly and have a short beyond-use date. This fifth of a series of articles on intravenous admixture preparation considerations represents an introduction on pH considerations, which is presented in two parts, pH basics and applications, covering pH Considerations - Basics (In part 5 of this series): Basics of pH, pKa and Dissociation Constants, pH and Solubility, pH and Stability; and pH Considerations - Applications (in part 6 of this series): Vehicle Characteristics, Selected Injectable Characteristics, IV Admixtures and Syringe Admixtures, and General Summary of pH Effects.

摘要

pH值对溶解度和稳定性的影响是注射剂剂型配方中的关键因素,在静脉混合液中更为复杂,因为添加剂和溶媒可能具有不同的pH值。这一点尤为重要,因为大量注射用药物需要进行一些配制工作,包括冻干粉末的溶解、输液药物剂量的稀释、用于肠外营养的葡萄糖、氨基酸、维生素和电解质的混合等。药物酸碱环境的变化涉及溶解度和稳定性特征,并且与pH值密切相关,具体如下:(1) 当溶液的pH值偏离最大溶解度的pH值时,药物可能会从溶液中析出;(2) 当溶液的pH值偏离最大稳定性的pH值时,药物可能会更快降解,有效期缩短。这是关于静脉混合液配制注意事项系列文章的第五篇,介绍了pH值相关注意事项,分两部分呈现,即pH值基础和应用,涵盖pH值注意事项 - 基础(本系列第5部分):pH值、pKa和离解常数的基础,pH值与溶解度,pH值与稳定性;以及pH值注意事项 - 应用(本系列第6部分):溶媒特性、特定注射剂特性、静脉混合液和注射器混合液,以及pH值影响的总体总结。

相似文献

1
Sterile Basics: Intravenous Admixture Preparation Considerations, Part 5: pH Considerations.无菌基础:静脉药物混合制剂的制备考量,第5部分:pH值考量
Int J Pharm Compd. 2020 Jul-Aug;24(4):305-309.
2
Intravenous Admixture Preparation Considerations, Part 6: pH Considerations -- Applications.静脉药物混合配制的注意事项,第6部分:pH值注意事项——应用
Int J Pharm Compd. 2020 Sep-Oct;24(5):397-402.
3
Sterile Basics: Intravenous Admixture Compounding, Part 1: Introduction and Overview of the General Guidelines for an Intravenous Admixture Compounding Program, and Compounding Personnel Considerations.无菌基础知识:静脉药物混合调配,第 1 部分:静脉药物混合调配程序的一般指南简介和概述,以及调配人员注意事项。
Int J Pharm Compd. 2023 Mar-Apr;27(2):123-139.
4
Sterile Basics: Intravenous Admixture Compounding, Part 2: Parenteral Vehicle Considerations.无菌基础知识:静脉药物混合调配,第 2 部分:肠外载体的考虑因素。
Int J Pharm Compd. 2023 May-Jun;27(3):223-229.
5
Sterile Basics of Compounding: Intravenous Admixture Compounding, Part 3: Preparation Procedures.调配无菌基础:静脉药物混合调配,第3部分:制备程序。
Int J Pharm Compd. 2023 Jul-Aug;27(4):305-313.
6
Basics of Sterile Compounding: Sterile Basics of Compounding Intravenous Admixtures, Part 4: Physicochemical Considerations.无菌配制基础:静脉药物混合液配制的无菌基础,第4部分:物理化学考量
Int J Pharm Compd. 2023 Sep-Oct;27(5):397-409.
7
Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates.无菌基础:静脉药物混合制剂的制备考量,第4部分:微粒
Int J Pharm Compd. 2020 May-Jun;24(3):215-220.
8
Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues.无菌调配基础:静脉药物混合调配准备的考虑因素,第 10 部分:包装和容器封闭问题。
Int J Pharm Compd. 2021 Jul-Aug;25(4):311-317.
9
Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation.静脉药物混合调配注意事项,第 9 部分 A:静脉药物混合调配差错的预防。
Int J Pharm Compd. 2021 Mar-Apr;25(2):131-139.
10
Intravenous Admixture Preparation Considerations, Part 9-B: Error Prevention in Intravenous Admixture Preparation.静脉药物混合调配注意事项 9-B 部分:静脉药物混合调配差错的预防。
Int J Pharm Compd. 2021 May-Jun;25(3):222-229.

引用本文的文献

1
A Narrative Review: Analysis of Supplemental Parenteral Nutrition in Adults at the End of Life.一篇叙述性综述:对临终成年患者补充肠外营养的分析
Pharmaceuticals (Basel). 2023 Dec 30;17(1):65. doi: 10.3390/ph17010065.